Seres Therapeutics reports Q1 net loss

Seres Therapeutics

05/05/2026 12:18

Overview

US biotechnology firm reports Q1 net loss, compared to prior-year gain from VOWST sale

Company's operating expenses fell about $6 mln yr/yr, while R&D costs increased

Seres expects to fund operations through Q3 2026, seeks partnerships and capital

Outlook

Seres expects clinical readout from SER-155 study in irEC in coming weeks

Company expects to fund operations through Q3 2026 based on current cash position

Seres is seeking partnerships and other capital sources to support pipeline development

Result Drivers

HIGHER R&D COSTS - Q1 R&D expenses rose due to increased facilities and manufacturing-related costs, partially offset by lower personnel expenses

LOWER ADMINISTRATIVE COSTS - General and administrative expenses fell, reflecting reduced personnel, professional services, and IT costs

NO MANUFACTURING SERVICES REVENUE - Absence of manufacturing services revenue and related expenses after completion of Nestlé transition services at end of 2025

Company press release: ID:nGNXbl0f48

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Collaboration Revenue
$358,000
Q1 EPS
-$2.08
Q1 Net Income
-$19.91 mln
Q1 Operating Expenses
$21.27 mln
Q1 Operating Income
-$20.91 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Seres Therapeutics Inc is $22.00, about 186.1% above its May 4 closing price of $7.69

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)